Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07348263

EFESO: Study on Juvenile Onset Eosinophilic Fasciitis

International Multicentre Cohort Study on Clinical Manifestations and Response to Therapy in Juvenile Onset Eosinophilic Fasciitis

Status
Recruiting
Phase
Study type
Observational
Enrollment
20 (estimated)
Sponsor
Meyer Children's Hospital IRCCS · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Eosinophilic fasciitis is a connective tissue disorder characterized by inflammation of the muscle fasciae, which is very rare in children. In juvenile-onset eosinophilic fasciitis (JEF), there may be severe joint involvement and skin manifestations may be less prevalent than in adults. It represents an important differential diagnosis of both juvenile-onset systemic sclerosis and localized scleroderma, and the correct classification of these patients is necessary to define a targeted diagnostic-therapeutic pathway. The diagnostic criteria proposed for eosinophilic fasciitis in the adult population do not necessarily require confirmation by skin biopsy, currently the "gold standard," which is an invasive procedure for pediatric patients; however, these criteria have never been directly applied to the pediatric population. From a therapeutic point of view, the combination of glucocorticoids and methotrexate is recommended for both adults and pediatric patients, but the data supporting this treatment in children are very limited, and there are no studies comparing the therapeutic approaches currently in use in pediatrics. Finally, there are no studies in the literature documenting the long-term prognosis of these patients in terms of functional limitations, quality of life, or complications related to the disease or treatments.

Conditions

Timeline

Start date
2025-05-15
Primary completion
2026-05-15
Completion
2027-05-15
First posted
2026-01-16
Last updated
2026-03-11

Locations

15 sites across 11 countries: United States, Croatia, Germany, Israel, Italy, Romania, Slovenia, Spain, Sweden, Turkey (Türkiye), United Kingdom

Source: ClinicalTrials.gov record NCT07348263. Inclusion in this directory is not an endorsement.